Merck & Co. Stock News

Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug.

This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Dividend growth picked up from companies in the first half of November, with 6 companies announcing 10%+ increases, including ADP, Roper Technologies, Atmos, and Snap-on. Other notable companies expecting dividend hikes include Motorola Solutions, McCorm...

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cidara Therapeutics, Inc. (NasdaqCM: CDTX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Cidara will receive $221.50 in cash for each share of Cidar...

Merck & Co., Inc. ( MRK ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michelle Kehily Conference Call Participants Elena Meng Michael Paas Stephen S. Morse Magdalena Sobieszczyk Presentation Unknown Attendee So our final panel of the day is about vaccines.

Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.

Cidara Therapeutics shares doubled, and then some, on Friday after Merck agreed to buy the biotech company for $9.2 billion.

Merck & Co Inc (NYSE:MRK, ETR:6MK) announced it has agreed to acquire Cidara Therapeutics Inc (NASDAQ:CDTX) in a $9.2 billion cash deal, paying $221.50 per share, more than double Cidara's stock price prior to the announcement. Shares of Merck slipped 1.5% to about $92 on the news, while Cidara shares surged 105% to $217.

Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion deal, accelerating efforts to broaden its respiratory portfolio as it prepares for the loss of exclusivity on its blockbuster cancer drug Keytruda later this decade.